Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295823 | 0.89 | APLNR (0.47) | SMN1; SMN2ALDH1A1CHRM2SLC2A1APLNR | |
| SCHEMBL12494308 | 0.85 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1HPGDAPLNRMEN1 | |
| SCHEMBL15383240 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1HPGDCHRM2SLC2A1 | |
| SCHEMBL11953338 | 0.82 | APLNR (0.49) | SMN1; SMN2SLC2A1APLNRMEN1KMT2A | |
| SCHEMBL11954292 | 0.80 | TP53 (0.46) | SMN1; SMN2APLNRMEN1KMT2AHTR2A | |
| SCHEMBL11300017 | 0.78 | TP53 (0.55) | SMN1; SMN2ALDH1A1APLNRMEN1KMT2A | |
| SCHEMBL12525710 | 0.76 | APLNR (0.49) | SMN1; SMN2ALDH1A1APLNRMEN1KMT2A | |
| SCHEMBL12492811 | 0.76 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1HPGDAPLNRMEN1 | |
| SCHEMBL15383304 | 0.76 | TP53 (0.42) | SMN1; SMN2ALDH1A1APLNRMEN1KMT2A | |
| SCHEMBL20530830 | 0.76 | APLNR (0.54) | SMN1; SMN2ALDH1A1HPGDAPLNRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8759334-B2 | Compounds useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2013-11-14 | — | — | US | disclosed |
| WO-2012098033-A1 | AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371198-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | SMN1; SMN2 3302/4885ALDH1A1 1373/4885HPGD 583/4885 |
| US-20130303515-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES | GOT2, GPR119, PC | SMN1; SMN2 3302/4885ALDH1A1 1373/4885HPGD 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.